StocksFundsScreenerSectorsWatchlists
JNJ

JNJ - Johnson & Johnson Stock Price, Fair Value and News

147.93USD+2.19 (+1.50%)Market Closed

Market Summary

JNJ
USD147.93+2.19
Market Closed
1.50%

JNJ Alerts

  • 1 major insider sales recently.

JNJ Stock Price

View Fullscreen

JNJ RSI Chart

JNJ Valuation

Market Cap

351.1B

Price/Earnings (Trailing)

9.99

Price/Sales (Trailing)

4.12

EV/EBITDA

15.18

Price/Free Cashflow

19.24

JNJ Price/Sales (Trailing)

JNJ Profitability

EBT Margin

17.69%

Return on Equity

51.11%

Return on Assets

20.98%

Free Cashflow Yield

5.2%

JNJ Fundamentals

JNJ Revenue

Revenue (TTM)

85.2B

Rev. Growth (Yr)

7.3%

Rev. Growth (Qtr)

0.21%

JNJ Earnings

Earnings (TTM)

35.2B

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

-84.44%

Breaking Down JNJ Revenue

Last 7 days

-2.1%

Last 30 days

-6.7%

Last 90 days

-9.9%

Trailing 12 Months

-10.3%

How does JNJ drawdown profile look like?

JNJ Financial Health

Current Ratio

1.16

Debt/Equity

0.38

Debt/Cashflow

0.88

JNJ Investor Care

Dividend Yield

3.22%

Dividend/Share (TTM)

4.7

Buy Backs (1Y)

7.51%

Diluted EPS (TTM)

13.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202381.0B82.3B83.7B85.2B
202276.3B73.2B69.8B80.0B
202184.2B89.2B91.4B78.7B
202082.7B80.5B80.9B82.6B
201981.6B81.3B81.7B82.1B
201878.7B80.7B81.4B81.6B
201772.2B72.5B74.4B76.5B
201670.2B70.9B71.6B71.9B
201573.6B71.9B70.5B70.1B
201471.9B73.5B74.4B74.3B
201368.6B70.0B70.5B71.3B
201265.0B64.9B65.9B67.2B
201162.1B63.4B64.4B65.0B
201062.5B62.6B62.5B61.6B
200962.6B61.4B60.5B61.9B
2008062.0B62.9B63.7B
200700061.1B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Johnson & Johnson

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 13, 2024
broadhurst vanessa
sold
-1,441,760
162
-8,891
evp, global corp affairs
Feb 13, 2024
duato joaquin
sold (taxes)
-237,880
157
-1,507
ceo and chairman of the board
Feb 13, 2024
wolk joseph j
acquired
-
-
1,780
exec vp, cfo
Feb 13, 2024
broadhurst vanessa
acquired
-
-
408
evp, global corp affairs
Feb 13, 2024
hait william
acquired
-
-
834
see remarks
Feb 13, 2024
swanson james d.
sold (taxes)
-30,780
157
-195
evp, cio
Feb 13, 2024
broadhurst vanessa
sold (taxes)
-32,990
157
-209
evp, global corp affairs
Feb 13, 2024
forminard elizabeth
acquired
-
-
651
executive vp, general counsel
Feb 13, 2024
decker robert j
sold (taxes)
-13,575
157
-86.00
vp corporate controller
Feb 13, 2024
fasolo peter
sold (taxes)
-74,820
157
-474
exec vp, chief hr officer

1–10 of 50

Which funds bought or sold JNJ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
SeaCrest Wealth Management, LLC
reduced
-48.47
-3,833,130
3,925,180
0.48%
Apr 18, 2024
CHAPIN DAVIS, INC.
reduced
-5.01
-145,797
3,377,200
1.23%
Apr 18, 2024
Capital Advisors, Ltd. LLC
reduced
-2.92
-11,000
530,000
0.07%
Apr 18, 2024
Exchange Capital Management, Inc.
added
32.22
636,442
2,539,190
0.41%
Apr 18, 2024
WESPAC Advisors SoCal, LLC
reduced
-32.71
-3,370,600
7,135,170
1.87%
Apr 18, 2024
Barry Investment Advisors, LLC
reduced
-1.67
-56,166
7,300,050
2.43%
Apr 18, 2024
WOODMONT INVESTMENT COUNSEL LLC
added
2.92
481,888
12,943,600
1.09%
Apr 18, 2024
IBEX WEALTH ADVISORS
added
95,166
504,467
505,000
0.14%
Apr 18, 2024
HT Partners LLC
reduced
-0.42
11,350
2,264,300
0.82%
Apr 18, 2024
Sharkey, Howes & Javer
reduced
-1.65
-2,179
292,335
0.05%

1–10 of 49

Are Funds Buying or Selling JNJ?

Are funds buying JNJ calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JNJ
No. of Funds

Unveiling Johnson & Johnson's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.53%
229,372,559
SC 13G/A
Jan 30, 2024
state street corp
5.52%
132,996,283
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
186,308,341
SC 13G/A
Feb 10, 2023
state street corp
5.45%
142,447,944
SC 13G/A
Feb 09, 2023
vanguard group inc
9.44%
246,826,621
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
198,802,769
SC 13G/A
Feb 14, 2022
state street corp
5.51%
144,996,127
SC 13G/A
Feb 10, 2022
vanguard group inc
8.92%
234,782,632
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
200,021,352
SC 13G/A
Feb 12, 2021
state street corp
5.47%
144,029,634
SC 13G

Recent SEC filings of Johnson & Johnson

View All Filings
Date Filed Form Type Document
Apr 16, 2024
8-K
Current Report
Apr 16, 2024
8-K/A
Current Report
Apr 10, 2024
3
Insider Trading
Apr 10, 2024
SC 13G
Major Ownership Report
Apr 05, 2024
DFAN14A
DFAN14A
Mar 27, 2024
PX14A6G
PX14A6G
Mar 13, 2024
DEFA14A
DEFA14A
Mar 13, 2024
DEFA14A
DEFA14A
Mar 13, 2024
DEF 14A
DEF 14A
Mar 13, 2024
ARS
ARS

Peers (Alternatives to Johnson & Johnson)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
351.1B
85.2B
-6.70% -10.33%
9.99
4.12
6.46% 95.94%
317.1B
60.1B
2.45% 9.70%
868.73
5.27
1.40% -97.49%
143.3B
46.5B
-8.14% -36.93%
-103.22
3.08
42.59% -114.62%
140.8B
28.2B
-3.32% 6.70%
20.96
4.99
7.09% 2.52%
82.4B
27.1B
-9.93% -21.39%
14.54
3.04
-0.60% 23.36%
14.3B
15.8B
-4.27% 50.53%
-24.85
0.9
6.17% 76.47%
MID-CAP
4.1B
4.7B
-0.96% -17.31%
-319.48
0.87
4.58% 90.97%
4.0B
1.7B
-14.12% -18.81%
11.16
2.39
49.61% 324.78%
3.1B
8.8B
-9.85% 14.21%
-5.31
0.36
7.79% -163.11%
1.9B
644.4M
-13.30% -10.60%
13.51
2.88
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-9.90% -28.22%
-3.8
1.8
24.65% 80.36%
21.7M
1.3M
-17.90% -49.05%
-2.11
16.65
-98.14% -109.18%
17.6M
-
-9.57% 32.48%
-0.96
0.22
2882.68% -138.52%
2.5M
19.6M
-30.19% -94.45%
-0.18
0.13
80.00% 43.08%
472.0K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Johnson & Johnson News

Latest updates
MarketBeat6 hours ago
The Motley Fool16 Apr 202409:45 pm
Investor's Business Daily16 Apr 202408:02 pm
Investopedia16 Apr 202402:11 pm

Johnson & Johnson Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue0.2%21,39521,35121,51920,89419,93919,99620,21519,8409,76923,33823,31222,32122,47521,08218,33620,69120,74720,72920,56220,02120,394
Gross Profit-1.0%14,59714,74515,05714,20713,85513,82413,89313,8228,26716,08815,72515,25814,66114,11011,75713,62913,61313,86213,62213,40613,433
  S&GA Expenses-15.6%4,5605,4006,6656,1384,2234,9756,2265,9382,6136,0006,0735,4326,4575,4314,9935,2036,0395,3745,5465,2195,991
EBITDA Margin2.5%0.27*0.27*0.26*0.24*0.32*0.31*0.29*0.30*0.32*0.30*0.31*0.30*---------
Interest Expenses-55.7%85.0019234621517751.0038.0010.0060.0020.0040.0063.0087.0044.0045.0025.0085.0048.0083.00102250
Income Taxes-68.4%2879081,618-6695018621,026713-4211823841,232-91.00847314713208-1061,43467380.00
Earnings Before Taxes-7.5%4,8265,2176,306-1,2873,8405,1725,1445,2031,2383,8496,6627,4291,6474,4013,9406,5094,2181,6477,0414,4223,122
EBT Margin5.2%0.18*0.17*0.17*0.16*0.24*0.24*0.21*0.22*0.24*0.21*0.23*0.21*---------
Net Income-84.4%4,04926,0285,144-68.003,5204,4584,8145,1494,7363,6676,2786,1971,7383,5543,6265,7964,0101,7535,6073,7493,042
Net Income Margin-0.2%0.41*0.41*0.14*0.14*0.21*0.21*0.19*0.21*0.22*0.20*0.20*0.18*---------
Free Cashflow-3.8%6,2746,5223,0582,3943,7635,3324,7183,3724,3177,5434,5013,397---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.9%167,558166,061191,686195,969187,378175,124177,724178,355182,018179,228176,440172,557174,894170,693158,380155,017157,728155,521155,117150,027152,954
  Current Assets-0.4%53,49553,70360,56764,38855,29465,23663,84760,42460,97959,88953,76952,53351,23757,57845,89244,22645,27444,33341,79941,98746,033
    Cash Equivalents10.8%21,85919,72821,18319,17012,88911,35510,98310,46314,48717,60414,33212,67113,98518,96511,17415,53017,30516,24914,37614,73418,107
  Inventory-0.2%11,18111,19812,88812,80910,26811,67511,43710,99010,38710,38710,1009,9529,3449,5999,4248,8689,0209,1739,2639,0868,599
  Net PPE5.7%19,89818,82120,57620,17417,98218,15218,35418,70118,96218,47818,63218,36718,76617,85517,59817,40117,65817,04817,24817,00017,035
  Goodwill1.2%36,55836,12445,44045,57536,04733,38334,16634,93525,43635,56935,81920036,3931,20033,89020033,63933,29133,6612,00030,453
Liabilities4.2%98,78494,833115,277125,100110,574100,525101,367103,646107,995108,956106,860106,723111,616106,22095,40293,72398,25797,31194,33291,07293,202
  Current Liabilities4.3%46,28244,37054,17060,37355,80245,54344,82143,39045,22644,56138,72140,93242,49338,84736,77233,68935,96435,16231,35329,11131,230
  Short Term Borrowings-10.8%3,4513,87011,70117,97912,7564,4244,3054,2973,7663,7983,1733,3502,6315,0785,3322,1901,2022,2991,7191,7082,796
  Long Term Debt-0.7%25,88126,05133,90134,92826,88627,60328,29228,85129,98530,13030,31030,26332,6357,50025,06225,39326,49426,91927,69927,66027,684
    LT Debt, Non Current-0.7%25,88126,05133,90134,92826,88627,60328,29228,85129,98530,13030,31030,26332,6357,50025,06225,39326,49426,91927,69927,66027,684
Shareholder's Equity-3.4%68,77471,22876,40970,86976,80474,59976,35774,70974,02370,27269,58065,83463,27864,47362,97861,29459,47158,21060,78558,95559,752
  Retained Earnings0.9%153,843152,536129,381124,558128,345127,917126,216124,380123,060121,092120,154116,508113,890114,831113,898112,901110,659109,242109,809106,650106,216
Accumulated Depreciation-100.0%-26,80530,64230,19325,55228,52928,79029,00128,71728,86928,56928,06328,03827,30726,45825,84625,67425,57725,65725,26224,816
Shares Outstanding0.4%2,5342,5232,6022,6062,6252,6292,6302,6292,6322,6332,6322,632---------
Minority Interest---1,260------------------
Float---430,000---472,000---445,000---363,000---368,000--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations5.0%7,8637,4894,1823,2575,3506,2845,5813,9795,7328,2905,3144,0748,3438,3833,4523,3586,3987,5275,9483,5436,244
  Share Based Compensation-39.9%178296382306213281366278215259354307160256326263160245314258156
Cashflow From Investing-147.3%-1,2022,541-3,7763,315-4,397-1,701-2,639-3,634-5,360-2,719-419-185-7,903-4,819-7,522-581-1,344-1,645-1,788-1,4172,228
Cashflow From Financing58.9%-4,655-11,317-5,9916,1381,700-3,925-2,261-4,385-3,436-2,207-3,279-5,125-5,6444,196-357-4,315-4,072-3,893-4,534-5,516-6,389
  Buy Backs-76.5%2169203813,5371,3202,1659731,5779963916311,4383214837061,7114261,6282,4862,2063,808

JNJ Income Statement

2023-12-31
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Income Statement [Abstract]   
Sales to customers$ 85,159$ 79,990$ 78,740
Cost of products sold26,55324,59623,402
Gross profit58,60655,39455,338
Selling, marketing and administrative expenses21,51220,24620,118
Research and development expense15,08514,13514,277
In-process research and development impairments313783900
Interest income(1,261)(490)(53)
Interest expense, net of portion capitalized772276183
Other (income) expense, net6,634810526
Restructuring489275209
Earnings before provision for taxes on income15,06219,35919,178
Provision for taxes on income1,7362,9891,377
Net earnings from continuing operations13,32616,37017,801
Net earnings from discontinued operations21,8271,5713,077
Net earnings$ 35,153$ 17,941$ 20,878
Net earnings per share   
Basic net earnings per share from continuing operations (in dollars per share)$ 5.26$ 6.23$ 6.76
Basic net earnings per share from discontinued operations (in dollars per share)8.620.601.17
Basic (in dollars per share)13.886.837.93
Diluted net earnings per share from continuing operations (in dollars per share)5.206.146.66
Diluted net earnings per share from discontinuing operations (in dollars per share)8.520.591.15
Diluted (in dollars per share)$ 13.72$ 6.73$ 7.81
Average shares outstanding   
Basic (in shares)2,533.52,625.22,632.1
Diluted (in shares)2,560.42,663.92,674.0

JNJ Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Jan. 01, 2023
Current assets:  
Cash and cash equivalents$ 21,859$ 12,889
Marketable securities1,0689,392
Accounts receivable trade, less allowances $166 (2022, $169)14,87314,039
Inventories11,18110,268
Prepaid expenses and other receivables4,5142,876
Total current assets of discontinued operations05,830
Total current assets53,49555,294
Property, plant and equipment, net19,89817,982
Intangible assets, net34,17538,489
Goodwill36,55836,047
Deferred taxes on income9,2798,947
Other assets14,1539,212
Noncurrent assets of discontinued operations021,407
Total assets167,558187,378
Current liabilities  
Loans and notes payable3,45112,756
Accounts payable9,6329,889
Accrued liabilities10,21210,719
Accrued rebates, returns and promotions16,00113,579
Accrued compensation and employee related obligations3,9933,049
Accrued taxes on income2,9932,220
Current liabilities of discontinued operations03,590
Total current liabilities46,28255,802
Long-term debt25,88126,886
Deferred taxes on income3,1933,991
Employee related obligations7,1496,542
Long-term taxes payable2,8814,306
Other liabilities13,39810,146
Noncurrent liabilities of discontinued operations02,901
Total liabilities98,784110,574
Commitments and Contingencies
Shareholders’ equity  
Preferred stock — without par value (authorized and unissued 2,000,000 shares)00
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)3,1203,120
Accumulated other comprehensive income (loss)(12,527)(12,967)
Retained earnings and Additional-paid-in-capital153,843128,345
Less: common stock held in treasury, at cost (Note 12) (712,765,000 shares and 506,246,000 shares)75,66241,694
Total shareholders’ equity68,77476,804
Total liabilities and shareholders’ equity$ 167,558$ 187,378
JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
 CEO
 WEBSITEjnj.com
 INDUSTRYPharmaceuticals
 EMPLOYEES65535

Johnson & Johnson Frequently Asked Questions


What is the ticker symbol for Johnson & Johnson? What does JNJ stand for in stocks?

JNJ is the stock ticker symbol of Johnson & Johnson. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Johnson & Johnson (JNJ)?

As of Thu Apr 18 2024, market cap of Johnson & Johnson is 351.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers. The fair value of Johnson & Johnson is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Johnson & Johnson is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JNJ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Johnson & Johnson a good stock to buy?

The fair value guage provides a quick view whether JNJ is over valued or under valued. Whether Johnson & Johnson is cheap or expensive depends on the assumptions which impact Johnson & Johnson's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JNJ.

What is Johnson & Johnson's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, JNJ's PE ratio (Price to Earnings) is 9.99 and Price to Sales (PS) ratio is 4.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JNJ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Johnson & Johnson's stock?

In the past 10 years, Johnson & Johnson has provided 0.064 (multiply by 100 for percentage) rate of return.